By Editor , 30 September 2026
Netwrix: 31% of Healthcare Orgs Hit by Unauthorized Identity Access

Frisco, Texas – September 30, 2026 -- Thirty-one percent of healthcare organizations experienced unauthorized identities accessing sensitive data in the past year, compared with 24% across other industries, according to new healthcare findings from Netwrix's 2026 Data and Identity Security Report. Among healthcare organizations that suffered an incident, 33% reported costs exceeding $250,000, versus 21% in other sectors.

By Editor , 30 September 2026
Arrowfly Launches AI for Engineers Platform, Sets 2027 Conference

Cleveland – September 30, 2026 -- Arrowfly has launched AI for Engineers, a year-round platform combining a dedicated news desk, an annual conference, original research, and an advisory board for engineers applying artificial intelligence across design, manufacturing, robotics, medtech, and energy work.

By Editor , 30 September 2026
Lilly's EBGLYSS Hits Primary Endpoint in Phase 3b Hand-Foot Eczema Trial

Indianapolis – September 30, 2026 -- Eli Lilly and Company (NYSE: LLY) said its EBGLYSS (lebrikizumab-lbkz) monotherapy met the primary and secondary endpoints of the Phase 3b ADtouch study at Week 16, with more than half of treated patients achieving clear or almost clear skin on hands and feet (HF-IGA 0/1), the company disclosed ahead of the European Academy of Dermatology and Venereology Congress in Vienna, running Sept. 30-Oct. 3.

By Editor , 30 September 2026
Knowles Launches A-Series Attenuators Covering DC to 20 GHz

Itasca, Illinois – September 30, 2026 -- Knowles Corporation (NYSE:KN) has introduced its new ATT A-Series Attenuators, expanding its RF portfolio to position the company as a one-stop source for high-performance RF signal chain components.

By Editor , 30 September 2026
Virtus Solis, Brae Systems Sign First-Ever Space Solar PPA

Troy, Michigan and Chicago – September 30, 2026 -- Virtus Solis Technologies and Brae Systems have closed a 20-year Power Purchase Agreement for space-based solar power, marking the world's first commercial orbital solar PPA and a multi-billion-dollar lifetime contract commitment.

By Editor , 30 September 2026
CUJO AI Launches Tool to Pinpoint Proxy-Hijacked Home Devices

Los Angeles – September 30, 2026 -- CUJO AI has introduced a new network intelligence capability that identifies the exact device inside a subscriber's home being used as a residential proxy, closing a detection gap that previously left operators able only to flag suspicious IP addresses without knowing which device was compromised.

By Editor , 30 September 2026
AppZen Launches AI Agents to Automate Corporate Card Compliance

San Jose – September 30, 2026 -- AppZen has launched Autonomous Cards, an AI agent layer that automates compliance, monitoring and spend intelligence for enterprise corporate card programs, as commercial card volume in the U.S. hit $2.23 trillion in 2024, up 4.5% year-over-year, according to the Nilson Report.

By Editor , 30 September 2026
TrackVia Launches AI Layer IRIS, MCP Support, Rebuilt Android App

Denver – September 30, 2026 -- TrackVia has expanded its Field Operations Intelligence platform with a new artificial intelligence layer called IRIS, enterprise AI connectivity, a rebuilt Android application and a modernized web interface, targeting organizations managing complex field operations across construction, manufacturing, healthcare, hospitality, education and government.

By Editor , 30 September 2026
Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

By Editor , 30 September 2026
Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.